Log In
Print this Print this

APO-go, apomorphine

  Manage Alerts
Collapse Summary General Information
Company Stada Arzneimittel AG
DescriptionSubcutaneous formulation of apomorphine
Molecular Target Dopamine receptor
Mechanism of ActionDopamine receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
PartnerKyowa Hakko Kirin Co. Ltd.;
Teva Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today